Skip to main content

FDA Investigating Hospitalizations Linked to Counterfeit Ozempic

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 9, 2023.

By Physician’s Briefing Staff HealthDay Reporter

WEDNESDAY, Nov. 8, 2023 -- The U.S. Food and Drug Administration has received at least three reports of people being hospitalized after taking counterfeit versions of semaglutide.

At least one of these reports includes mention of a counterfeit version of the Novo Nordisk medication Ozempic, CBS News reported. Ozempic and Wegovy, another semaglutide medication made by Novo Nordisk, have been tough to find for months as millions of Americans turn to them for weight loss.

In total, 42 reports that mention the use of counterfeit semaglutide were submitted to the FDA Adverse Event Reporting System through the end of September, CBS News reported. Of those, 28 were classified as "serious," with outcomes that included deaths. All were submitted to the FDA by Novo Nordisk.

However, the records do not prove the counterfeits directly caused the adverse events. An FDA spokesperson told CBS News that the agency has "no new information to share regarding reports of adverse events" linked to semaglutide counterfeits.

Meanwhile, Novo Nordisk has said that it is working with the FDA to make consumers aware of the counterfeits and how they differ from the company's products.

"In close collaboration with FDA, we have taken measures to create awareness of the potential for counterfeit products. We have developed a company statement that... includes a guide for identifying counterfeits," a Novo Nordisk spokesperson told CBS News.

CBS News Article

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...

Bariatric Surgery Tied to Lower Risk of MACE, Death in Obesity, Sleep Apnea

FRIDAY, June 28, 2024 -- Metabolic surgery is associated with significantly lower risk of major adverse cardiovascular events (MACE) compared with nonsurgical management among...

Exercise + GLP-1 RA Effective for Weight Loss While Preserving BMD

THURSDAY, June 27, 2024 -- For adults with obesity, without diabetes, combining exercise with the glucagon-like peptide-1 receptor agonist (GLP-1 RA), liraglutide, is effective...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.